Drug profile · INN
amoxicillin
ALPHAMOX 250
amoxicillin (ALPHAMOX 250) is a bacterial penicillin-binding protein inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — amoxicillin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 53
- Data quality
- 0.89
Quick answer
amoxicillin (ALPHAMOX 250) is a bacterial penicillin-binding protein inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026015039
THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1
granted -
WO 2025211975
AGONISTES DU RÉCEPTEUR DE L'OREXINE
granted -
US 12076377
Variant sulfatase enzymes with enhanced properties
granted -
US 11931463
All-in-one fixed-dose combination for treating Helicobacter pylori infection
granted -
US 11878011
Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
granted -
US 11154614
Method for producing virus like particles
granted -
US 11135172
Rifabutin-based compositions and methods for treating Helicobacter pylori infection
granted -
US 11028153
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
granted -
US 10487140
Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins
granted -
US 10238606
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted -
US 10233450
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 10106792
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9988630
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9873875
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9603806
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted -
US 9518262
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9498445
Pharmaceutical compositions for the treatment of Helicobacter pylori
granted -
US 9441227
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9365849
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
granted -
US 9186411
Pharmaceutical composition
granted
Frequently asked questions
What is amoxicillin?
amoxicillin (ALPHAMOX 250) is a bacterial penicillin-binding protein inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for amoxicillin?
ALPHAMOX 250 is a marketed brand name for amoxicillin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amoxicillin?
amoxicillin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.